(AVP) and oxytocin (OT) peptides in the developing rat brain and pituitary were studied using antibodies and complementary separation methods that permitted a quantitative radioimmunoassay (WA) analysis of precursor, intermediate, and completely processed forms of the peptides. Precursor forms of the peptides were first detected in rat brain as early as embryonic day (E) 15 for AVP and El7 for OT. Proteolytic cleavage products of the precursors were detected 1 d later for both peptides. AVP was present in a fully processed (amidated) form immediately (E16) and throughout fetal development. OT was cleaved from its precursor starting on El6 but remained in an intermediate (C-terminal extended) form until E21, when amidated OT was first detected in the pituitary. Hence, Pro-AVP processing in the fetus was immediate and complete, whereas Pro-OT processing in the fetus was much slower and incomplete, resulting in the generation of partially processed, nonamidated stable forms of the peptide (OT-GlylO, OT-Glylo-Lysll, and OT-Gly10-Lys11-Arg12).
The presence of OT-Gly10-Lys11-Arg'2 as a major, stable intermediate form, indicated that the in viva pattern of endoproteolytic cleavage occurred principally at the C-terminus of the pair of basic amino acids at the tripeptide spacer sequence (Gly-Lys-Arg) in the precursor.
Although both precursors were first expressed nearly simultaneously in the brain, the steady-state levels of the precursors were very different throughout fetal life. From El 6-E21, the quantities of AVP precursors and peptides were 5 to lo-fold greater than those of OT, suggesting a much higher level of precursor biosynthesis in the AVP neurons. In addition to these differences in the regulation of biosynthesis and processing, AVP peptides were axonally transported to the pituitary 3 d earlier than OT peptides, and in far greater (20-fold) abundance.
The early pres-ence and abundance of amidated AVP in the brain and pituitary suggests a trophic function for this peptide during development.
Arginine vasopressin (AVP), oxytocin (OT), and their associated neurophysins (Np-AVP and Np-OT) are synthesized principally in magnocellular neurosecretory neurons located in the paraventricular (PVN) and the supraoptic (SON) nuclei in the hypothalamus (for reviews, see Caste1 et al., 1984; Sofroniew, 1985) . It is now well established that both peptide hormones and their Nps are first synthesized as large precursor proteins that are then transformed by a variety of posttranslational processing steps to form the biologically active hormones (reviewed in Gainer, 1983; Ivell et al., 1983; Douglas et al., 1984; Loh et al., 1984) . A large number of studies on the ontogeny of the hypothalamoneurohypophysial system (HNS) have found that the AVP peptide and the neurons that synthesize this peptide appear relatively early [around embryonic day (E) 16-171 in fetal development, whereas the OT peptide is not present until about the time of birth [i.e., between E20 to postnatal day (PN) 0] ( Leclerc and Pelletier, 1977; Choy and Watkins, 1979; Watkins and Choy, 1979; Boer et al., 1980a, b; Buijs et al., 1980; Khachaturian and Sladek, 1980; Krisch, 1980; Sinding et al., 19801 Sladek et al., 1980; Boer, 1987) . However, from these data it was not possible to evaluate whether the delayed appearance of the OT compared with the AVP was due to a delay in gene expression of the peptide prohormones or to other cellular mechanisms. In an attempt to examine this issue, found in immunocytochemical studies, using monoclonal antibodies directed specifically against Np-OT and Np-AVP and their respective prohormones (Ben-Barak et al., 1985) , that both cell types were expressing their peptide prohormones (i.e., Np immunoreactivity) early in development (i.e., around E 16-l 7). Given the above data, Whitnall et al. (1985) suggested that the apparent paradox of an early appearance of both prohormones in fetal development but the lack of fully processed OT (in contrast to AVP) could be explained by a differential development of posttranslational processing in these 2 related neurons. However, the antibodies used in the above study could not distinguish between prohormones and processed neurophysins, and it remained unclear whether the OT prohormone was incompletely processed or not processed at all during fetal life.
In this study, we test this hypothesis of differential processing in OT and AVP neurons during development by using quantitative radioimmunoassay (RIA) analyses that can detect the (Land et al., 1982; Ivell et al., 1983; Ivell and Richter, 1984) , it is possible to predict the theoretical intermediate forms of both peptides. We used such peptides to generate specific antibodies and RIAs that could measure the partially processed (carboxy-terminal extended) forms of AVP and OT. As a result of these studies, we report here that (1) OT and AVP or their respective prohormones are present in fetal rat brain (E15-E21) with an approximately 5-to lo-fold greater expression of AVP versus OT prohormone throughout these developmental stages, (2) posttranslational processing mechanisms are significantly delayed in OT versus AVP neurons, so that AVP is completely processed to amidated AVP as early as El 6, whereas amidated OT is not detectable until E2 1, (3) the principal stable intermediate form of OT is OT-Glylo-LysllArglZ, indicating that the endopeptidase involved in in vivo processing cleaves on the carboxyl side of the arginine, and (4) the transport of AVP to the neural lobe of the pituitary precedes that of OT by at least 3 d. A preliminary report of some of these findings has been presented elsewhere Tables 1 and 2 .
Immunological analyses Radioimmunoassay. Determination of immunoreactive material by liquid-phase RIA was performed as follows. Reaction mixtures containing 100 ~1 lz51-tracer (annroximatelv 7000 cnm of AVP or OT). diluted in Kreb's Ringer (125-t& NaCl, 4.5 mM KCl, 1.5 mM MgSb,, 2.0 mM CaCl,, 2 mM HEPES, and 1.5 mg/ml BSA, pH 7.4), 100 ~1 standard (1.95-1000 pg/tube AVP or OT) or unknown sample, and 400 pl of antisera (at a dilution providing 30-50% binding), all in a total volume of 600 ~10.1 M Na phosphate buffer containing 1.5 mg/ml BSA, pH 7.4 (RIA buffer), were incubated, under equilibrium conditions, for 48 hr at 4°C. Incubation was terminated by the addition of 1.26 ml icecold ethanol (68% final concentration), and bound complex was separated from unbound tracer by centrifugation at 1500 x g for 30 min at 4°C. The supematant was discarded, and the pellet (bound fraction) was counted for radioactivity. Nonspecific binding (3-5%) was determined in the absence of antibody and was subtracted from every tube. The amount of immunoreactive material was determined using a standard curve of synthetic AVP and OT (the lower limit of assay sensitivity for both peptides was 3 pg/tube). RIA results were calculated using a logit transformation of the raw data [Fortran IV nroaram (RIAPROG) 
Materials and Methods

Materials
Animals. Sprague-Dawley rats (Zivic-Miller Labs, Allison Park, PA) of various ages were used in this study: embryonic, early postnatal, and adult. These 3 groups will be referred to as El 5-E2 1, PNO-PN2 1, and adult. Pregnancy was determined by the presence of a copulation plug, and the first day of gestation was the day following insemination.
Radioactivecompounds. [8-Arginine]1251-vasopressin (2200 Ci/mmol) and 1251-oxytocin (2200 Ci/mmol) were purchased from DuPont-New England Nuclear Corp. (Boston).
Hormones and analogs. 8-Arginine vasopressin and oxytocin were a gift from Ferring Pharmaceuticals (Malmo, Sweden). C-terminally extended forms of vasopressin (AVP-Glyio, AVP-G; AVP-Gly'O-Lys", AVP-GK, AVP-Glyl"-Lys1~-Arg12, AVP-GKR) and oxytocin (OT-GlylO, OT-G; OT-GlylO-Lys", OT-GK; OT-GLYI"-LYSl-ARG'", OT-GKR) were synthesized by Dr. J. Rivier from the Clayton Foundation Laboratories for Peptide Biology at the Salk Institute and were obtained from Dr. M. K&en (NICHD, Bethesda, MD).
Other chemicals and reaaents. BSA (RIA arade). trvnsin (TPCK treated, N-o-p-tosyl-L-lysine chloromethyl ketone (TLCK), HEPES (N-2-hydroxyethyl-piperazine-p-2 ethanesulfonic acid) and Columns and high-voltage electrophoresisplates. Sep-Pak C,, reversephase columns were purchased from Waters Associates and thin-layer chromatography plates (cellulose, Anacil C, 250 pm) for high-voltage electrophoresis were obtained from Analab, Inc. (North Haven, CT).
Immunological reagents. Studies on the content of brain of HNS hormones and their posttranslational processing mechanisms require antibodies that can recognize and distinguish between the various forms of cleaved hormones, i.e., fully (amidated) and partially processed (Cterminally extended) forms (see Fig. 1 for theoretical peptide intermediates and final hormones). After screening various AVP and OT antisera, the following antibodies were chosen for this study: anti-vasopressin (AVP-VA4) and anti-oxytocin (OT-VAl7), which were raised and characterized in our laboratory (Altstein et al., 1988) . Anti-vasopressin (AVP-LD) (Moore et al., 1977) and anti-oxytocin (OT-LD) were Cross-reactivity analysis. Antisera were characterized by analyzing their cross-reactivities with the peptide intermediates and final hormone peptides that are assumed to result from the in vivo processing of the prohormones (see Fig. 1 for theoretical intermediates). Cross-reactivity analysis was performed by liquid-phase RIA (see above), except that the unknown samples were substituted with serial dilutions of known hormone analogs. Samples were prepared in RIA buffer and incubated with specific antisera and iodinated tracers as described above, and cross-reactivity was determined by comparing the potency of fully processed (amidated) and partially processed (C-terminally extended) forms of AVP and OT to displace iodinated AVP or OT from a given antibody.
The results of these studies (Tables 1 and 2 ) demonstrated that the AVP and OT-snecific antibodies could be divided into those that onlv recognized the C-terminally amidated forms (AVP-JR1 and OT-MM) and those that recognized both forms, i.e., C-terminally amidated and C-terminally extended nonamidated peptides (AVP-LD, AVP-VM, OT-LD, and OT-VA17). For the AVP-specific antibodies, AVP-JR1 was found to be directed mainly towards the C-terminal region of AVP, whereas AVP-LD and AVP-VA4 were found to be directed mainly towards the N-terminal region of the hormone since they cross-reacted with C-terminally extended forms of AVP and truncated AVP (desGly-NH,-AVP) ( Table 1) . Amone the OT-snecific antibodies OT-MM was found to be directed mainly t;wards the C-terminal region of OT, whereas OT-LD and OT-VA 17 were found to be directed mainly towards the N-terminal region ofthe hormone (Table 2 ). All AVP and OT antibodies were found to be specific for their homologous hormones and no crossreactivity was detected with OT of AVP and their analogs, respectively. Experimental procedures Tissue dissections. On the day of the experiment the mothers were anesthetized and the uterus was immediately dissected. The fetuses were removed and decapitated, and the heads were kept on ice during the time of dissection. Brains and pituitaries containing the neural lobe (obtained separately only after E 18) were removed and quickly frozen on glass slides placed on dry ice. Twelve to fifteen brains and pituitaries were used at each embryonic stage, and 8 brains or pituitaries were used at each postnatal stage. For the embryonic stages, the entire brain was homogenized. However, postnatal brains were further dissected to remove the hypothalamus and median eminence, which were homogenized together for analysis. Over 99% of the AVP and OT in the rat CNS is found in these dissected brain areas postnatally (Boer et al., 1980~; Caste1 et al., 1984; Sofroniew, 1985; Boer, 1987) .
Tissue extraction. The above tissues were transferred to precooled y Relative displacement factor represents the ratio (in %) of AVP concentration required to displace 50% of Y-AVP from an antibody to the concentration required to get the same degree of displacement with any other hormone or analog. Cross-reactivity was determined from displacement curves as described in Methods using 1251-AVP as a tracer and 6-10 dilutions of hormone or analog, in duplicates, within the following range of concentrations:
AVP-JRl, 3.90 pgkube-20 &tube; AVP-LD, 19.5 pgkube-100 ng/tuk, AVP-VA4, 1.95 pgkube-1 t&tube. Numbers in parentheses indicate final antibody dilutions. LVP, Lys*-vasopressin;
AVT, vasotocin; n.t., not tested.
glass-glass homogenizers containing 10 ml (per 10 brains) or 1 ml (per 10 pituitaries) of 0.1 N hydrochloric acid (HCl) and homogenized manually. Samples were centrifuged at 12,100 x g for 15 min at 4°C and the supematant (S 1) was used for the analysis of fully processed forms of AVP and OT by means of RIA as described above. The remaining sample was treated with trichloroacetic acid (TCA, 10% final concentration) for 2 hr on ice and spun at 10,000 x g for 10 min at 4°C. The resulting supematant (S2) was ether-washed, lyophilized; resuspended in half She original volume 0.1 M Na phosphate buffer containing 1.5 ma/ml BSA. DH 7.4 (RIA buffer) and assaved for fullv nrocessed and pa&ally processed (C-terminally'extendedj forms of AVP and OT by means of RIA and high-voltage electrophoresis (HVE) chromatography (see below). The pellet (P2) was ether-washed, air-dried, dissolved in either 2.0 ml (brain) or 0.14 ml (pituitary) 10 mM Tris-HCl, pH 8.0 (trypsinization buffer), and incubated in the presence or absence of trypsin (10 &ml) for 2 hr at 37°C. Incubation was terminated by TLCK (0.025 mg/ml), and samples were then assayed for tryptic cleavage products by means of RIA as described above.
Determination of peptide recoveries in extracts. The validity of the extraction procedure &as evaluated by determining the recovery of labeled or unlabeled svnthetic AVP and OT. Iodinated AVP or OT was added to 4 ml of 0.1 N HCl containing 4 hypothalami and was extracted as described above. Radioactivity was monitored in Sl and S2 supernatants, and recovery was calculated to be 70 and 60% for Sl and S2, respectively, for both hormones. Recovery of peptide-IR in S2 after TCA precipitation was also determined using unlabeled hormones. AVP and OT (750 rig/ml) were subjected to TCA precipitation as described above in the presence of 150 &ml BSA. Samples were spun and etherwashed, and the S2 supematant was tested for hormone content using RIA standard curves as described in the cross-reactivity section. Recovery in S2 was determined using AVP-JR1 (1:45,000) and OT-MM (1: 100,000) antisera and was calculated from the ratio (in %) of AVP or OT concentration required to displace 50% of 1251-AVP or 1251-OT, respectively, before and after TCA precipitation. Recovery was found to be 64 and 54% for AVP and OT, respectively.
High-voltage electrophoresis. TCA-treated supematants from 10 brains y Relative displacement factor represents the ratio (in %) of OT concentration required to displace 50% of iz51-AVP from an antibody to the concentration required to get the same degree of displacement with any other hormone or analog. Cross-reactivity tested using l*SI-OT as a tracer and 6-10 dilutions of hormone or analog, in duplicates, within the following range ofconcentrations:
OT-MM, 1.95 pgkrbe-1 @/tube, OT-LD, 19.5 pg/tub+lOO ng/tuk, OT-AVl7,1.95 pg/tube-1 rig/tube. All other details are as described in the legend to and pituitaries (S2) were prepared as described above and used for HVE analysis. Prior to the HVE, extracts were partially purified on a SepPak C,, reverse-phase column. Samples were applied onto the column and washed with 5 ml of 0.1% trifluoracetic acid (TFA) to remove nonpeptide contaminants. The peptides were eluted from the Sep-Pak by two 1 ml washes of 80% methanol, containing 0.1% TFA. The eluate was dried, reconstituted in 20 rlO.01 N HCl, and analyzed by HVE on cellulose plates in a pH 2 system (formic acid/acetic acid/water, 20:80: 900). The electrophoresis was carried out at 900 V, and front migration (15.5 cm from origin) was determined by a methyl green marker. The plate was then cut in 1 cm fractions beginning 1 cm below the origin, peptides were extracted from the cellulose with 500 ~10.1 N HCl, and all fractions were assayed for immunoreactive material by means of RIA as described below. Markers (AVP, OT, and their C-terminally extended forms) were run on adjacent lanes and visualized by fluorescamine (Mandez and Iai, 1973) and by RIA. Sample recovery was evaluated using synthetic AVP and OT, and was >98% for Sep-Pak columns and 20% for HVE.
Results
Studies on the oxytocin and vasopressin genes (Land et al., 1982 (Land et al., , 1983 Ivell et al., 1983; Ivell and Richter, 1984) and the biosynthesis of their prohormones (reviewed in Gainer, 1983) have clarified the structural forms of the prohormone precursors.
Based on our current understanding of peptide precursor processing (Douglas et al., 1984; Loh et al., 1984; Gainer et al., 1985) , it is possible to deduce the theoretical intermediate peptide forms produced by processing the precursors to the final peptide forms (Fig. 1) . In the sections below we systematically evaluate the presence of the precursors and intermediate forms in the rat brain during development, using specific antibodies in RIA which are particularly appropriate for such an analysis (see Tables 1 and 2 , and Methods). OT-MM) that recognize only the amidated forms of the hormone in RIAs on brain or pituitary extracts before TCA precipitation (S 1, see Methods). These data are illustrated in Figure   2 , separately for the brain and pituitary. The data are similar to previous analyses of these peptides during ontogeny, which have reported a delayed appearance of OT versus AVP peptides (see introduction). AVP was first detected by RIA on El7 in the brain, whereas OT could only be first detected on E21 in the pituitary. AVP, on the other hand, was measurable in the pituitary on El 8 (the first embryonic day that the pituitary could be isolated as a distinct entity). In view of the immunocytochemical evidence that the precursor for OT was expressed significantly earlier than E21, we next examined whether unamidated intermediate forms of OT were present at these early stages.
Quantitative RIA analysis of all forms of cleaved peptides (fully and partially processed) was performed using antibodies (anti-AVP-LD and anti OT-LD) that recognize both amidated and unamidated (C-terminally extended) peptides. The antibodies used in these analyses were found to react with all forms of the AVP or OT peptides, as well as, to some extent, the peptide hormone sequences contained within the precursors (M. Altstein, unpublished observations). Therefore, separation of cleaved hormones from precursors was performed by TCA precipitation of the brain and pituitary extracts, and the resultant supernatants (S2, see Methods) were used for the determination of the fully and partially processed (cleaved) peptides in brain and neural lobe. The data, illustrated in Figure 3 , show that cleaved forms of OT are detectable in the rat brain as early as El8 and continue to increase throughout fetal development. Interestingly, however, the first detection in the pituitary was at E21, suggesting that primarily amidated forms of OT were being transported to the neural lobe at this time (compare Figs.  1 and 2) . Since the thresholds of detection in all the assays were comparable (i.e., 3 pg/tube, see Methods), the finding of signif- (right) found at different stages of development. Hormone content was determined by RIA using antibodies (AVP-JR 1, 1:45,000, and OT-MM, 1: 100,000) that recognize the fully processed amidated hormones (see Tables 1 and 2 ), and either brain or neural lobe of the pituitary extracts before TCA precipitation (Sl in Methods). Each point represents the mean of 3-5 serial dilutions in duplicates (ranging from 1:2 to 1:32 for brain extracts and 1:20 to 1: 160 for pituitary extracts) with a variation of less than 8%. Values less than 0.03 rig/brain or neural lobe were below the detection limit of the assays. Note that while AVP is detectable on El 7 in the brain and on E 18 in the pituitary, OT is not detectable until E2 1 (in the neural lobe).
icant OT immunoreactivity in the brain with the OT-LD antibody (Fig. 3) but not the amide-requiring OT-MM antibody (Fig. 2 ) strongly suggested that primarily unamidated OT peptide intermediates were present in the brain during fetal life.
The differences in the immunoreactivities obtained with these 2 classes of antibodies allowed for comparisons of the content of partially and completely processed forms of AVP and OT. Figure 4 (left panel) shows that no extended forms of AVP (AVP-X-IR) could be detected in the brain at any developmental stage and that only the fully processed amidated hormone was significantly present. OT extended forms (OT-X-IR), however, were found in the brain beginning at El8 and throughout development, indicating that the OT precursor is synthesized during embryonic stages but is not fully processed to form amidated OT (Fig. 4, right panel) . However, by PN7 both forms of OT were substantially found in the brain, and the ratio of amidated to unamidated hormone increased from 0.5 1 at PN7 to 0.98 at PN2 1 (Fig. 4, right panel) . Analysis of neural lobe extracts showed that the first detection of AVP (on El 8) and OT (E2 1) consisted essentially of completely processed (amidated) forms (see also  Tables 3 and 4) . Although partially processed forms of OT immunoreactivity could be detected at all embryonic stages, the overall level of the OT immunoreactivity was relatively low compared with AVP levels during fetal life (Tables 3, 4).
Characterization of the intermediate forms of OT
Since the antibodies that recognized the partially processed peptides were unable to distinguish between the different C-ter- Figure 3 . Content of total cleaved AVP and OT peptides [i.e., both fully processed (AVP) and partially processed forms (AVP-X)] in brain (left) and neural lobe (right) extracts at various embryonic and postnatal stages. Hormone content was determined by RIA using antibodies (AVP-LD, 1: 100,000, and OT-LD, 1:60,000) that recognize both amidated (fully processed) and C-terminally extended (partially processed) forms of the hormone (see Tables 1 and 2 ), and either brain or neural lobe supematants after TCA precipitation (S2 in Methods). Values were corrected for recovery after TCA precipitation (64 and 54% recovery for AVP and OT, respectively). Each point represents the mean of 3-5 serial dilutions in duplicates (ranging from 1:2 to 1:32 for brain extracts and 1:40 to 1:640 for neural lobe extracts) with a variation of less than 6%. Values less than 0.03 &brain or neural lobe were below the detection limits of the assays. Note that in contrast to the data in Figure 2 , these data indicate that OT is present at early embryonic stages (El 8) but in an unamidated form. minally extended forms, further characterization of these forms was performed by a combination of RIA with HVE. Analysis of PN14 brain and neural lobe extracts for AVP-like immunoreactivity with both sets of antibodies, after HVE fractionation, revealed only one peak of immunoreactivity above baseline, and this peak comigrated with amidated AVP (Fig. 5) . These studies confirmed the absence of partially processed forms of AVP in both the brain and the neural lobe (Fig. 5) .
A similar analysis for OT-like immunoreactivity is shown in Figure 6 . The data indicate that both amidated and C-terminally extended forms of the hormone are present in the brain at PN7-PN21 (Fig. 6, left panel) , and that all 3 possible intermediate forms resulting from OT processing (i.e., OT-Gly, OT-Gly-Lys, and OT-Gly-Lys-Arg; see Fig. 1 ) were present. In contrast to the brain, the neural lobe contained only one peak of immunoreactivity, and this comigrated with amidated OT, confirming the paucity of partially processed forms of OT in this region (Fig. 6, right (1: 100,000) antisera, respectively, and the content of partially processed hormones (AVP-X and OT-X) was calculated from the differences between the immunoreactivities determined using AVP-LD and AVP-JR1 antibodies, and OT-LD and OT-MM antibodies, respectively. Experimental details are as described in the legend to Figure 3 and Methods. Note that while AVP in the brain is virtually completely processed during fetal life, OT in the brain remains unamidated until after birth. analyzed for fully and partially processed forms of AVP. Brain (0.4 ml) and neural lobe (10 ~1) supematants (S2 in Methods) were passed through a Sep-Pak column, eluted, dried, resuspended in 20 ~10.0 1 N HCl, and applied on a HVE plate for electrophoresis as described in Methods. At the end of the run, 50 ~1 cellulose HCl extracts were analyzed for AVP or AVP-X immunoreactivity. AVP immunoreactivity (M) was determined using AVP-JR1 antiserum (1:45,000), and AVP-X immunoreactivity (C---0) was calculated from the difference between the immunoreactivities of the AVP-VA4 (1: 16,000) and AVP-JR 1. Electrophoretic positions of standards (depicted by arrows) were visualized by fluorescamine and also measured by means of RIA as described in Methods. Abbreviations: A VP-G, AVP-glycine; A VP-GK, AVP-glycine-lysine; AVP-GKR, AVP-glycine-lysine-arginine (see Fig. 1 ). Figure 6 . HVE of brain and neural lobe extracts (postnatal days 7-21) analyzed for fully and partially processed forms of OT. Brain (1.60 ml) and pituitary (0.42 ml) supematants (S2 in Methods) were applied on an HVE plate, after a Sep-Pak step, and electrophoresed as described in the legend to Figure 5 , except that in this experiment 100 ~1 (brain) and 2 ~1 (neural lobe) aliquotes of the 500 ~1 cellulose HCl extract were analyzed for OT and OT-X immunoreactivity. OT immunoreactivity (0---0) was determined using OT-MM antiserum (1: 1 OO,OOO), and OT-X immunoreactivity (M) was calculated from the difference between the immunoreactivities of OT-VA-17 (1:60,000) and OT-MM. Electrophoretic positions of standards (arrows) were visualized by fluorescamine and measured by means of RIA as described in Methods. Value of OT-GK was corrected for the cross-reactivity of anti-OT-VA17 with OT-GK. Abbreviations: OT-G, OT-glycine; OT-GK, OT-glycine-lysine; OT-GKR, OTglycine-lysine-arginine (see Fig. 1 ).
Gly-Lys-Arg and OT-Gly-Lys, and appearance of OT-Gly, which is resistant to the enzymatic activity. Figure 7 shows that treatment of brain extracts with CP-B caused both extended forms (OT-Gly-Lys and OT-Gly-Lys-Arg) in the brain extract to disappear and add to the immunoreactivity of the OT/OT-Gly peak as expected.
Evaluation of precursor content and total A VP and OT during development
In the above sections we demonstrated that the extent of processing of the OT precursor (Pro-OT) to peptide forms was much more immature than that of the AVP precursor (Pro-AVP) during embryonic development and that partially processed (but cleaved) forms of OT, in contrast to AVP, were abundant even during postnatal stages (Fig. 4) . In addition, the absolute content of all AVP peptide forms were 5-to lo-fold higher than those of OT peptide forms throughout the embryonic period ( Fig. 3 ; Tables 3, 4). One possible explanation for the dominance of cleaved AVP could be that Pro-OT is not proteolytically cleaved with the efficiency of cleavage of Pro-AVP in vivo. In order to check for this possibility, the quantities of Pro-AVP and Pro-OT were independently analyzed at the various developmental stages and compared to levels of the cleaved hormone. Since direct RIA determinations of prohormone content are not technically feasible at present, we used an indirect method (see Methods). This method was based on the fact that trypsin treatment of the precursor releases the peptide hormones from their N-termini, which can then be detected by antibodies that react with C-terminally extended forms (see Fig. 1 for expected tryptic cleavage products of Pro-AVP and Pro-OT). The use of such an approach required the separation of the prohormones from the cleaved peptides, and this was done by TCA precipitation of the precursors and analysis of hormone immunoreactivity in the P2 pellet after trypsin treatment (see Methods).
The results of the above experiment are shown in Tables 3  and 4 , together with a quantitative summary of the AVP and OT immunoreactives found in precursors and cleaved peptide forms in brain and pituitary at various stages of development. Several conclusions are apparent from the analysis of precursor immunoreactivity. (1) As might be expected, the detectable immunoreactivity in precursor form precedes that detectable in cleaved peptide forms by 1 d (i.e., on E 15 for Pro-AVP and E 17 for Pro-OT). (2) At no time in development does the pituitary contain measurable precursor immunoreactivity (data not shown), and both peptides found in this tissue are always predominantly in the amidated form. (3) Cleavage of both precursors to peptide products occurs early in development, although the ratio of the Pro-OT to OT peptides in brain is generally higher than that of the Pro-AVP/AVP peptide during fetal life (e.g., for OT the ratio at E21 is 1.9, whereas for AVP at this time the ratio is 0.30). The significance of this observation is unclear and could reflect either a difference in efficiency of precursor proteolytic processing, a difference in storage of cleaved peptides in brain, or both. It is interesting, however, that this difference in ratio persists into late postnatal stages (e.g., at PN2 1 the OT ratio is 0.45, whereas the AVP ratio is 0.06). (4) Even accounting for the contributions of precursor immunoreactivities, the total AVP immunoreactivity in the brain and pituitary is 5-l 0 times greater than that of OT throughout fetal life. These values approach equivalence during the later stages of postnatal development and equality by PN40 (Tables 3, 4 ).
Discussion
In this paper, we have presented a quantitative analysis of the ontogeny of AVP and OT precursor biosynthesis and posttranslational processing in the rat CNS. Previous quantitative studies of AVP and OT ontogeny indicated that OT was not present in the brain during early fetal development (see introduction), whereas immunocytochemical studies from our laboratory, using monoclonal antibodies that cross-reacted with the neurophysin moiety in the AVP and OT precursors, indicated that neurons containing Pro-AVP and Pro-OT immunoreactivity were present as early as E 16 and continued to increase throughout embryonic development . This apparent contradiction between the previous quantitative RIA studies and the qualitative immunochemical study cited above prompted us to reexamine this issue by an RIA analysis that could quantitatively assess the precursors and the intermediate and fully processed (amidated) forms for both AVP and OT. The results are in concordance with the immunocytochemical findings of an early expression of the OT gene in the brain and support the hypothesis that the Pro-OT precursor is incompletely processed during fetal life to unamidated forms of OT. In addition to resolving the apparent contradiction in the literature on this subject, these quantitative data have uncovered significant differences in the biosynthetic states of the AVP and OT neurons during fetal development.
The differences we have found include (1) different steadystate levels of the precursors and peptides, with AVP neurons far exceeding (5-to lo-fold) OT neurons in this regard; (2) different commitments to posttranslation processing mechanisms, so that AVP neurons produce amidated AVP peptide products as early as El6 (Table 3) , whereas the complete processing of OT first occurs 1 d prior to birth (E21; Table 4); and (3) a significantly earlier and more abundant axonal transport of AVP peptides (in comparison to OT peptides) to the posterior pituitary (i.e., AVP first detected at E18, and OT at E21 in the posterior pituitary), and by E21 there is about 20-fold more AVP than OT in this neurohemal organ. It is clear from these observations that the AVP neurons are significantly more precocious than OT neurons during development.
The estimates of first detection of AVP and OT gene expression in the brain by the RIA methods we have used compare favorably with alternative (but qualitative) methods. Immunocytochemical assays first detected AVP-and OT-expressing neurons at El6 and in situ hybridization histochemical techniques have detected AVP mRNA (OT mRNA was not studied) at E 16 at the earliest (Reppert and Uhl, 1987) . Our RIA analysis first detected Pro-AVP at El5 a day earlier (Table 3) and Pro-OT at El7 a day later (Table 4) . HVE of a brain extract from postnatal day 14 before and after carboxypeptidase B (CP-B) treatment. Two milliliters of brain extract (S2 in Methods) were lvophilized. resusnended in 500 ~1 of CP-B buffer (50 mM Tris-HCl, pH i.d), and the sample was incubated in the presence and absence of CP-B (40 &ml) for 2 hr at 37°C. The enzymatic reaction was stopped with 0.1 N HCl (final concentration), and the treated and untreated samples were passed through a Sep-Pak column and electrophoresed as described in Methods. Immunoreactivity was determined using 100 ~1 of the cellulose extract and OT-VA 17 antiserum (1:60,000). Values were corrected as described in the legend to Figure  6 , and standard peptide markers were visualized as described in the legend to Figure 5 . the immunocytochemical studies. Given the low levels of Pro-OT expressed in fetal rat brain, it is perhaps not surprising that immunocytochemistry (a technique that can detect immunoreactivity in single secretory vesicles; see Ben-Barak et al., 1985) is more sensitive than the RIA method. What is surprising is that Pro-AVP could be detected by RIA on E15, a day before immunocytochemical detection. Although both the AVP and OT neurons are capable of synthesizing precursors on about the same embryonic day, it is clear that the level of gene expression is much greater throughout fetal life in the AVP neurons. This is reflected by the lo-fold greater content of AVP precursors and peptide products than OT (compare Tables 3 and 4) . Although no comparisons of OT and AVP mRNA in early fetal brain are available, Van To1 (1987) has shown using Northern blot analysis of PVN and SON mRNA that at E20 in the rat hypothalamus, AVP mRNA is significantly greater than OT mRNA, consistent with the quantitative RIA data on translated products presented here.
It is known that the magnocellular neurons in the rat SON and PVN undergo their terminal cell divisions between E 12 and El 5 (Ifft, 1972; Altman and Bayer, 1978a, b) , so that the differences found in biosynthetic levels and posttranslational processing (from El 5 to E2 1) are not likely to be the result of a Whitnall et al. (1985) suggested a differential rate of axonal outgrowth between the OT and AVP neurons, which was indicated by abundant Pro-AVP-containing axons in the internal zone of the median eminence at E21, whereas very few Pro-OT axons could be found in this region of the hypothalamoneurohypophysial tract at that time. This interpretation is consistent with our findings of a 3 d lag between AVP and OT appearance in the posterior pituitary (the site of axon termination) and of the 20-fold greater content of AVP versus OT in the pituitary at E21 (Figs. 2 and 3 , Tables 3 and  4) .
The systematic developmental delay observed in posttranslational processing of the OT peptides during fetal life is particularly interesting. Amidated OT is not produced until E2 1, and even neonatal brain contains substantial OT-GKR intermediates (Fig. 6 ). Presumably this block is occurring at the carboxypeptidase-B-like and a-amidating enzymatic steps in processing . Since these processing steps proceed to completion in the AVP neurons, this "regulation" appears to be cell-specific and is not due to a general developmental lag in these processing mechanisms in the hypothalamus. It will be interesting, in the future, to determine whether gene expression of these enzymes is delayed in OT neurons versus AVP neurons. Regulation at the level of processing has also been reported for a variety of other peptide-synthesizing cells Mains, 1978, 1981; Mainsand Eipper, 1979 , 1981 Kriegeret al., 1980; Seizinger et al., 1984; Kream et al., 1985; Sato and Mains, 1985; Rehfeld, 1986) .
This developmental lag in OT processing gave us a unique opportunity to observe the nature of the proteolytic cleavage mechanism as it occurs in vivo. The presence of a stable OTGly-Lys-Arg intermediate (Fig. 6) has significance for the mechanism of prohormone processing since it indicates that the prohormone converting enzyme cleaves at the C-terminus of the ArgJ2 in the commonly found paired basic cleavage site (LysArg) in vivo (see Fig. 1 ). While this conclusion is clear for the OT-Gly-Lys-Arg intermediate, the occurrence of stable OT-GlyLys and OT-Gly intermediates (Figs. 6 and 7) is not unequivocal with respect to this point since these intermediates could have been generated either directly by the endopeptidase or, alternatively, by a carboxypeptidase-B action following cleavage. In any case, to our knowledge, this is the first experimental evidence for the utilization of the carboxyl side of the Arg in the Lys-Arg pair as a cleavage site in any neuropeptide prohormone in vivo. In addition, this is consistent with our previous report that the AVP-precursor is cleaved principally at the carboxyl side of the Arglz in vitro by a putative prohormone converting enzyme that was isolated from the neural lobe (Parish et al., 1986) and that this same site is cleaved in vitro by neural lobe endopeptidase in a Pro-OT,-,, synthetic peptide (Clamagirand et al., 1986) .
It is intriguing that fully amidated AVP is abundantly present in the developing rat brain and pituitary at least 3 weeks before the AVP has its prominent antidiuretic effects on the kidney (approximately at PN20, at the end of the suckling period; Rajerison et al., 1976) . Since AVP receptors have been reported to be present in the embryonic brain, it has been proposed previously that AVP may play a role as a trophic factor in the brain during embryonic and early postnatal development (see Boer, 1987) . Similar arguments have been put forth for other neuropeptides (e.g., POMC-derived peptides, TRH and VIP), which are reputed to influence neuronal proliferation, migration, differentiation, and the organization of functional pathways during brain development (see Stratton et al., 1976; Swaab et al., 1978; Aranda and Stem, 1983; Lauder, 1983; Brenneman et al., 1985; Handelmann, 1985; Brenneman and Eiden, 1986; Zagon and McLaughlin, 1986) . The observation that Np-AVP was mitogenic for cultured hypothalmic glia (Worley and Pickering, 1984) may be related to the early arrival of AVP peptides in the posterior pituitary. The initiation of pituicyte (i.e., neural lobe astrocyte) differentiation has been correlated with the first appearance of neurosecretory (presumably AVP; see Fig. 3 and Table 3 ) axons in the neural lobe (Dellman and Sikora, 198 l), and hence, it is possible that pituicyte differentiation is, in part, mediated by Pro-AVP derived peptides. The biological significance of the delayed development in OT biosynthesis, processing, and axonal transport is unclear at present. One possibility is that the extended forms of OT may themselves play a role in fetal brain development. Alternatively, the OT may bind to the AVP receptors in fetal brain and pituitary but not possess the biological activity ofthe AVP and, thereby, could potentially act as a natural antagonist. Further investigation is necessary not only to uncover the biological significance of this differential regulation of biosynthesis and processing in the developing AVP and OT neurons, but also the molecular mechanisms that underlie it.
